Eli Lilly Benelux
De berekende faillissementskans van Eli Lilly Benelux over 12 maanden bedraagt 0,4% (zeer laag). De jaarrekening over 2024 toont een eigen vermogen van €19,95M en een nettoresultaat van €6,09M. Het eigen vermogen blijft stabiel over de neergelegde boekjaren (±0,1% per jaar). De solvabiliteit is beter dan 58% van 549 sectorgenoten (boekjaar 2024). Het bedrijf is actief sinds 1969 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen.
| Eigen vermogen | €19,95M |
| Netto resultaat | €6,09M |
| Werknemers (VTE) | 86,9 |
| Beter dan sector | 58% |
Sterk profiel, met stabiliteit als uitschieter.
Alle 5 assen zijn berekend uit gegevens die Checked heeft ingelezen.
Statistische inschatting op basis van openbare bronnen, geen kredietadvies of vaststelling. Hoe berekenen we dit?
De volledige opbouw van de score, de scoregeschiedenis per boekjaar en de indicatieve kredietlimiet zitten in Kantoor S.
Bekijk plannen →Hoe berekenen we dit?
De trend is een robuuste mediaan van alle paarsgewijze hellingen tussen de boekjaren (Theil-Sen), zodat één afwijkend jaar de lijn niet kan kapen. Voor strikt positieve reeksen rekenen we ook een loggroei-variant (samengestelde jaargroei) en kiezen we de variant die de cijfers het best beschrijft.
De zone rond de projectie is 1,8 × de mediane absolute afwijking van de trend, en verbreedt per jaar vooruit (×1 / ×1,6 / ×2,2), met een minimum van 8% van de laatste waarde. Dit is een indicatieve marge, géén statistisch betrouwbaarheidsinterval.
Een reeks waarvan de afwijkingen meer dan 35% van het niveau bedragen, is te volatiel: dan tonen we bewust géén projectie. Elke projectie veronderstelt ongewijzigd beleid en kent geen niet-publieke informatie (orderboek, contracten, financieringsrondes).
| Kengetal | Dit bedrijf | Sectormediaan | Positie in de sector |
|---|---|---|---|
| Solvabiliteit | 38,8% | 31,0% | |
| Nettoresultaat | €6,09M | €47k | |
| Eigen vermogen | €19,95M | €468k | |
| Personeelskosten | €24,82M | €494k | |
| Werknemers (VTE) | 86,9 | 7,5 |
Toon 14 andere kengetallen
| Boekjaar | 2024 |
|---|---|
| Neerlegging | volledig |
| Omzet | €142,73M |
| EBITDA | €7,92M |
| Nettoresultaat | €6,09M |
| Cashflow | €6,14M |
| Personeelskosten | €24,82M |
| Belastingen op het resultaat | €2,33M |
| Dividenden | €6,00M |
| Totaal activa | €51,44M |
| Eigen vermogen | €19,95M |
| Schulden | €31,50M |
| waarvan ≤ 1 jaar | €31,50M |
| waarvan > 1 jaar | - |
| Werkkapitaal | €19,69M |
| Werknemers (VTE) | 86,9 |
| 2024 | |
|---|---|
| Current ratio | 1,63 |
| Quick ratio | 1,63 |
| Werkkapitaalratio | 38,3% |
| Solvabiliteit | 38,8% |
| Debt / equity | 1,58 |
| Langetermijnschuldgraad | - |
| Interest coverage | 973,58 |
| Bruto rentabiliteit | 31,3% |
| Netto rentabiliteit | 4,3% |
| ROA | 11,8% |
| ROE | 30,5% |
| EBITDA-marge | 5,5% |
| Klantenkrediet (DSO) | 92d |
| Leverancierskrediet (DPO) | 59d |
| Voorraadrotatie | - |
| Voorraaddagen (DSI) | - |
Volledige jaarrekening (22 posten)
| Post | Code | 2024 |
|---|---|---|
| Balans, Activa | ||
| TOTAAL ACTIVA | 20/58 | €51,44M |
| Vaste activa | 21/28 | €253k |
| Materiële vaste activa | 22/27 | €252k |
| Financiële vaste activa | 28 | €1k |
| Vlottende activa | 29/58 | €51,19M |
| Vorderingen op ten hoogste één jaar | 40/41 | €50,89M |
| Balans, Passiva | ||
| TOTAAL PASSIVA | 10/49 | €51,44M |
| Eigen vermogen | 10/15 | €19,95M |
| Inbreng / kapitaal | 10/11 | €12,89M |
| Reserves | 13 | €6,91M |
| Overgedragen winst (verlies) | 14 | €141k |
| Schulden | 17/49 | €31,50M |
| Schulden op ten hoogste één jaar | 42/48 | €31,50M |
| Handelsschulden op ten hoogste één jaar | 44 | €15,84M |
| Resultatenrekening | ||
| Omzet | 70 | €142,73M |
| Bedrijfsresultaat | 9901 | €7,87M |
| Financiële opbrengsten | 75 | €554k |
| Financiële kosten | 65 | €8k |
| Resultaat vóór belasting | 9903 | €8,42M |
| Belastingen op het resultaat | 67/77 | €2,33M |
| Resultaat van het boekjaar | 9904 | €6,09M |
| Te bestemmen resultaat | 9905 | €6,09M |
-
Jan TheuwisAssociate director marketingStaatsblad-akte 24097965 (01-07-2024)Actief01-07-2024 → heden
-
Sébastien MassartAssociate director market access & corporate affairsStaatsblad-akte 24097965 (01-07-2024)Actief01-07-2024 → heden
-
Tinne GlasséeSenior director medical leadStaatsblad-akte 24097965 (01-07-2024)Actief05-09-2023 → heden
2 gebeurtenissen
- 01-07-2024 Benoemd· Senior director medical lead
- 05-09-2023 Benoemd· Senior director medical shared services
-
Sandrine FerrièreBestuurderStaatsblad-akte 20103941 (09-09-2020)Actief23-06-2016 → heden
6 gebeurtenissen
- 09-09-2020 Benoemd· Bestuurder
- 24-01-2020 Benoemd· Administrator
- 13-07-2018 Benoemd· Bestuurder
- 30-11-2017 Benoemd
- 21-03-2017 Benoemd· Bestuurder
- 23-06-2016 Benoemd· Hr manager
-
Frédéric ClaisBestuurderStaatsblad-akte 20103941 (09-09-2020)Actief09-12-2015 → heden
5 gebeurtenissen
- 09-09-2020 Benoemd· Bestuurder
- 24-01-2020 Benoemd· Administrator
- 13-07-2018 Benoemd· Bestuurder
- 09-12-2015 Benoemd· Bestuurder
- 09-12-2015 Benoemd· Gedelegeerd bestuurder
Historisch, niet recent bevestigd (7)
-
Jan-Pieter ClaeysSales & marketing lead diabetes and oncology belgiumStaatsblad-akte 19018888 (06-02-2019)Niet recent bevestigdlaatst bevestigd in akte van 2019
3 gebeurtenissen
- 06-02-2019 Benoemd· Sales & marketing lead diabetes and oncology belgium
- 30-11-2017 Ontslagen
- 23-06-2016 Benoemd· Sales and marketing lead for diabetes
-
Ana Carla FranchSite engagement manager, clinical operations belgiumStaatsblad-akte 18108907 (13-07-2018)Niet recent bevestigdlaatst bevestigd in akte van 2018
3 gebeurtenissen
- 13-07-2018 Benoemd· Site engagement manager, clinical operations belgium
- 30-11-2017 Ontslagen
- 23-06-2016 Benoemd· Csm leader na
-
Jérôme BareyManager compta générale, contrôle interneStaatsblad-akte 17167384 (30-11-2017)Niet recent bevestigdlaatst bevestigd in akte van 2017
-
Ernst & Young Réviseurs d'Entreprises SC SCRLRechtspersoonAuditorStaatsblad-akte 16120339 (29-08-2016)Niet recent bevestigdlaatst bevestigd in akte van 2016
-
Anne-Pascale HoutekieRegulatory affairs manager and responsible pharmacistStaatsblad-akte 16085317 (23-06-2016)Niet recent bevestigdlaatst bevestigd in akte van 2016
-
Karin FrijnsCustomer meeting services associateStaatsblad-akte 16085317 (23-06-2016)Niet recent bevestigdlaatst bevestigd in akte van 2016
-
Eric JanvierBestuurderStaatsblad-akte 04086479 (14-06-2004)Niet recent bevestigdlaatst bevestigd in akte van 2004
Vaste vertegenwoordigers (3)
-
Carlo-Sébastien D'AddarioReprésentant permanent du commissaireStaatsblad-akte 25117863 (18-09-2025)Vaste vertegenwoordiger18-09-2025 → heden
-
Elisabeth Van VleymenRepresentantStaatsblad-akte 24097965 (01-07-2024)Vaste vertegenwoordiger- → 01-07-2024
-
Fanny VerspeeltRepresentantStaatsblad-akte 24097965 (01-07-2024)Vaste vertegenwoordiger- → 01-07-2024
Voormalige bestuurders (17)
-
Bénédicte Van MaeleMedical shared services leadStaatsblad-akte 19018888 (06-02-2019)Voormalig06-02-2019 → 05-09-2023
2 gebeurtenissen
- 05-09-2023 Ontslagen· Senior director medical shared services
- 06-02-2019 Benoemd· Medical shared services lead
-
Bert MackenSales and brand manager oncologyStaatsblad-akte 17167384 (30-11-2017)Voormalig30-11-2017 → 06-02-2019
2 gebeurtenissen
- 06-02-2019 Ontslagen· Sales and marketing leader oncology
- 30-11-2017 Benoemd· Sales and brand manager oncology
-
Catherine de MûelenaereHead of marketing benelux and nordicStaatsblad-akte 17167384 (30-11-2017)Voormalig30-11-2017 → 06-02-2019
2 gebeurtenissen
- 06-02-2019 Ontslagen· Head of marketing benelux and nordic
- 30-11-2017 Benoemd· Head of marketing benelux and nordic
-
Egbert ThomasArea director of elanco benelux and nordicStaatsblad-akte 16085317 (23-06-2016)Voormalig23-06-2016 → 06-02-2019
3 gebeurtenissen
- 06-02-2019 Ontslagen· Area director of elanco benelux and nordic
- 30-11-2017 Ontslagen
- 23-06-2016 Benoemd· Area director of elanco benelux and nordic
-
Michèle SangeleerMedical directorStaatsblad-akte 16085317 (23-06-2016)Voormalig23-06-2016 → 06-02-2019
2 gebeurtenissen
- 06-02-2019 Ontslagen· Medical shared services lead
- 23-06-2016 Benoemd· Medical director
| Commissaris / bedrijfsrevisor | IBR/IRE-nummer | Periode |
|---|---|---|
| EY Réviseurs d'Entreprises SRLActief Commissaire |
- | 18-09-2025 → heden |
Toon 2 eerdere commissarissen
| Carlo-Sébastien d'Addario Commissaire opgevolgd door EY Réviseurs d'Entreprises SRL in 2025 |
- | 13-09-2022 → 18-09-2025 |
| Ernst & Young Réviseurs d'Entreprises SC SCRL Commissaire opgevolgd door Carlo-Sébastien d'Addario in 2022 |
- | 24-01-2020 → 13-09-2022 |
| NACE primair | Groothandel in farmaceutische en medische artikelen(46460) |
| Rechtsvorm | NV(014) |
| Oprichtingsdatum | 19-06-1969 |
| Status | Actief |
| Postcode | 1000 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 21804D1348/00E000 | Brussel | 5.332 m² | 1 · 3.876 m² | 36,3 m · 10 verd. |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
Wij kennen 35 Staatsblad-aktes van dit bedrijf. Daarvan is er nog geen enkele gelezen: wat erin staat, is hier niet vastgesteld en ook niet weerlegd.
18-09-2025 2 bestuurders benoemd
- EY Réviseurs d'Entreprises SRL, Commissaire
- Carlo-Sébastien D'Addario, Représentant permanent du commissaire
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "EY R\u00E9viseurs d\u0027Entreprises SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent du commissaire",
"person": {
"rrn": null,
"name": "Carlo-S\u00E9bastien D\u0027Addario",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}23-08-2024 General meeting · Board meeting · Officer appointment · Officer reappointment
- Publication: 23/08/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 19/06/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 13/03/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Board meeting: 15/05/2024 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: bestuurder, start_date: 2024-03-13 · Bayer N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · AbbVie N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · Eli Lilly Benelux N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · Pfizer N.V.
- Officer reappointment: role: bestuurder, start_date: 2024-03-13 · GlaxoSmithKline Pharmaceuticals N.V.
- Officer resignation: date: 2024-03-13, role: bestuurder · Takeda Belgium N.V.
- Officer appointment: role: ondervoorzitter van de Raad van Bestuur, start_date: 2024-05-15 · An Van Gerven
- Permanent representative · Werner De Prins
- Permanent representative: start_date: 24/05/2024 · Bart Vermeulen
- Permanent representative: start_date: 14/06/2024 · Niels Hessmann
- Statute amendment · Algemene Vereniging van de Geneesmiddelenindustrie
Technische details
{
"facts": [
{
"date": "2024-08-23",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 23/08/2024",
"value": "23/08/2024",
"object": null,
"subject": "e1"
},
{
"date": null,
"type": "filing",
"quote": "neergelegd/ontvangen op 19 JUNI 2024 ter griffie van de Nederlandstalige ondernemingsrechtbank Brussel",
"value": "19/06/2024",
"object": null,
"subject": "e1",
"date_suspect": "2024-06-19"
},
{
"date": "2024-03-13",
"type": "general_meeting",
"quote": "BUITENGEWONE ALGEMENE VERGADERING VAN 13 MAART 2024",
"value": "13/03/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "board_meeting",
"quote": "VERGADERING VAN DE RAAD VAN BESTUUR VAN 15 MEI 2024",
"value": "15/05/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-13",
"type": "officer_appointment",
"quote": "Benoeming van: Bayer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. AbbVie N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 2. Eli Lilly Benelux N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 3. Pfizer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 4.GlaxoSmithKline Pharmaceuticals N.V.",
"value": {
"role": "bestuurder",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "bestuurder",
"term": null,
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_resignation",
"quote": "Ontslag van: 1. Takeda Belgium N.V.",
"value": {
"date": "2024-03-13",
"role": "bestuurder"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "13/03/2024",
"role": "bestuurder"
}
},
{
"date": "2024-05-15",
"type": "officer_appointment",
"quote": "Op de Raad van Bestuur van 15 mei 2024 werd mevrouw An Van Gerven tot ondervoorzitter van de Raad van Bestuur benoemd.",
"value": {
"role": "ondervoorzitter van de Raad van Bestuur",
"start_date": "2024-05-15"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"role": "ondervoorzitter van de Raad van Bestuur",
"term": null,
"start_date": "15/05/2024"
}
},
{
"type": "permanent_representative",
"quote": "Bayer N.V. (BE 0404.754.571) heeft als vaste vertegenwoordiger de heer Werner De Prins.",
"value": null,
"object": "e2",
"subject": "e12"
},
{
"date": "2024-05-24",
"type": "permanent_representative",
"quote": "Sanofi Belgium N.V. (BE 0464.435.901) heeft als nieuwe vaste vertegenwoordiger vanaf 24/05/2024 de heer Bart Vermeulen in opvolging van de heer Johan Heylen.",
"value": {
"start_date": "24/05/2024"
},
"object": "e9",
"subject": "e10"
},
{
"date": "2024-06-14",
"type": "permanent_representative",
"quote": "Bayer N.V. (BE 0404.754.571) heeft als nieuwe vaste vertegenwoordiger vanaf 14/06/2024 de heer Niels Hessmann in opvolging van de heer Werner De Prins.",
"value": {
"start_date": "14/06/2024"
},
"object": "e2",
"subject": "e13"
},
{
"type": "statute_amendment",
"quote": "De voorgestelde wijzigingen aan de statuten werden goedgekeurd door de Buitengewone Algemene Vergadering van 13 maart 2024",
"value": null,
"object": null,
"subject": "e1"
}
],
"act_meta": {
"outcome": "clean",
"postfix": [
"filing date 2024-06-19 outside [pub-60d, pub] -\u003E nulled (garbled stamp?)"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 27430,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0404.754.571",
"kind": "company",
"name": "Bayer N.V.",
"attrs": {
"seat": "J.E. Mommaertslaan 14, 1831 Diegem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie N.V.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux N.V.",
"attrs": {
"seat": "Markiesstraat 1, 1000 Brussel"
}
},
{
"id": "e5",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer N.V.",
"attrs": {
"seat": "Pleinlaan 17, 1050 Elsene"
}
},
{
"id": "e6",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals N.V.",
"attrs": {
"seat": "avenue Fleming 20, 1300 Wavre"
}
},
{
"id": "e7",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "An Van Gerven",
"attrs": {}
},
{
"id": "e9",
"kbo": "0464.435.901",
"kind": "company",
"name": "Sanofi Belgium N.V.",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Bart Vermeulen",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Johan Heylen",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Werner De Prins",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Niels Hessmann",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {}
}
]
}23-08-2024 Act object · General meeting · Officer appointment · Officer reappointment
- Act object: Nomination administrateurs - nomination vice-présidente Conseil d'administration - modifications aux statuts - nouveaux représentants permanents des administrateurs · Association Générale de l'Industrie du Médicament
- Publication: 23/08/2024 · Association Générale de l'Industrie du Médicament
- Filing: 19/06/2024 · Association Générale de l'Industrie du Médicament
- General meeting: 13/03/2024 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: administrateur, start_date: 2024-03-13 · Bayer S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · AbbVie S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · Eli Lilly Benelux S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · Pfizer S.A.
- Officer reappointment: role: administrateur, start_date: 2024-03-13 · GlaxoSmithKline Pharmaceuticals S.A.
- Officer resignation: date: 2024-03-13, role: administrateur · Takeda Belgium S.A.
- Statute amendment: Modifications aux statuts approuvées par l'AGE du 13 mars 2024 (articles 2, 5, 9, 12, 16, 28 et dispositions transitoires) · Association Générale de l'Industrie du Médicament
- Board meeting: 15/05/2024 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Vice-Présidente, start_date: 2024-05-15 · An Van Gerven
- Permanent representative · Werner De Prins
- Permanent representative: start_date: 24/05/2024 · Bart Vermeulen
- Permanent representative: start_date: 14/06/2024 · Niels Hessmann
Technische details
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Nomination administrateurs - nomination vice-pr\u00E9sidente Conseil d\u0027administration - modifications aux statuts - nouveaux repr\u00E9sentants permanents des administrateurs",
"value": "Nomination administrateurs - nomination vice-pr\u00E9sidente Conseil d\u0027administration - modifications aux statuts - nouveaux repr\u00E9sentants permanents des administrateurs",
"object": null,
"subject": "e1"
},
{
"date": "2024-08-23",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 23/08/2024 - Annexes du Moniteur belge",
"value": "23/08/2024",
"object": null,
"subject": "e1"
},
{
"date": null,
"type": "filing",
"quote": "neergelegd/ontvangen op 19 JUNI 2024",
"value": "19/06/2024",
"object": null,
"subject": "e1",
"date_suspect": "2024-06-19"
},
{
"date": "2024-03-13",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE EXTRAORDINAIRE DU 13 MARS 2024",
"value": "13/03/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-03-13",
"type": "officer_appointment",
"quote": "Nomination de : Bayer S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. AbbVie S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 2. Eli Lilly Benelux S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 3. Pfizer S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 4.GlaxoSmithKline Pharmaceuticals S.A.",
"value": {
"role": "administrateur",
"start_date": "2024-03-13"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "administrateur",
"start_date": "13/03/2024"
}
},
{
"date": "2024-03-13",
"type": "officer_resignation",
"quote": "D\u00E9mission de: 1. Takeda Belgium S.A.",
"value": {
"date": "2024-03-13",
"role": "administrateur"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "13/03/2024",
"role": "administrateur"
}
},
{
"date": "2024-03-13",
"type": "statute_amendment",
"quote": "Les modifications propos\u00E9es aux statuts ont \u00E9t\u00E9 approuv\u00E9es par l\u0027Assembl\u00E9e G\u00E9n\u00E9rale Extraordinaire du 13 mars 2024",
"value": "Modifications aux statuts approuv\u00E9es par l\u0027AGE du 13 mars 2024 (articles 2, 5, 9, 12, 16, 28 et dispositions transitoires)",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 15 MAI 2024",
"value": "15/05/2024",
"object": null,
"subject": "e1"
},
{
"date": "2024-05-15",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 15 mai 2024, Madame An Van Gerven a \u00E9t\u00E9 d\u00E9sign\u00E9e comme Vice-Pr\u00E9sidente.",
"value": {
"role": "Vice-Pr\u00E9sidente",
"start_date": "2024-05-15"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"role": "Vice-Pr\u00E9sidente",
"start_date": "15/05/2024"
}
},
{
"type": "permanent_representative",
"quote": "Bayer S.A. (BE 0404.754.571) a d\u00E9sign\u00E9 comme repr\u00E9sentant permanent Monsieur Wemer De Prins.",
"value": {
"start_date": null
},
"object": "e2",
"subject": "e9"
},
{
"date": "2024-05-24",
"type": "permanent_representative",
"quote": "Sanofi Belgium S.A. (BE 0464.435.901) a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 24/05/2024 Monsieur Bart Vermeulen, succ\u00E9dant \u00E0 Monsieur Johan Heylen.",
"value": {
"start_date": "24/05/2024"
},
"object": "e10",
"subject": "e11"
},
{
"date": "2024-06-14",
"type": "permanent_representative",
"quote": "Bayer S.A. (BE 0404.754.571) a d\u00E9sign\u00E9 comme nouveau repr\u00E9sentant permanent \u00E0 partir du 14/06/2024 Monsieur Niels Hessmann, succ\u00E9dant \u00E0 Monsieur Werner De Prins.",
"value": {
"start_date": "14/06/2024"
},
"object": "e2",
"subject": "e13"
}
],
"act_meta": {
"outcome": "clean",
"postfix": [
"filing date 2024-06-19 outside [pub-60d, pub] -\u003E nulled (garbled stamp?)"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 28008,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 Bruxelles",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0404.754.571",
"kind": "company",
"name": "Bayer S.A.",
"attrs": {
"seat": "J..E. Mommaertslaan 14, 1831 Diegem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue du Marquis 1, 1000 Bruxelles"
}
},
{
"id": "e5",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "Boulevard de la Plaine 17, 1050 Ixelles"
}
},
{
"id": "e6",
"kbo": "0403.066.474",
"kind": "company",
"name": "GlaxoSmithKline Pharmaceuticals S.A.",
"attrs": {
"seat": "avenue Fleming 20, 1300 Wavre"
}
},
{
"id": "e7",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium S.A.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "An Van Gerven",
"attrs": {}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Werner De Prins",
"attrs": {}
},
{
"id": "e10",
"kbo": "0464.435.901",
"kind": "company",
"name": "Sanofi Belgium S.A.",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Bart Vermeulen",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Johan Heylen",
"attrs": {}
},
{
"id": "e13",
"kbo": null,
"kind": "person",
"name": "Niels Hessmann",
"attrs": {}
},
{
"id": "e14",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}01-07-2024 3 bestuurders benoemd, 2 ontslagnemend
- Tinne Glassée, Senior director medical lead
- Sébastien Massart, Associate director market access & corporate affairs
- Jan Theuwis, Associate director marketing
- Elisabeth Van Vleymen, Representant
- Fanny Verspeelt, Representant
Technische details
{
"events": [
{
"kind": "director_out",
"role": "Representant",
"person": {
"rrn": null,
"name": "Elisabeth Van Vleymen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Senior Director Medical Lead",
"person": {
"rrn": null,
"name": "Tinne Glass\u00E9e",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Representant",
"person": {
"rrn": null,
"name": "Fanny Verspeelt",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Associate Director Market Access \u0026 Corporate Affairs",
"person": {
"rrn": null,
"name": "S\u00E9bastien Massart",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Associate Director Marketing",
"person": {
"rrn": null,
"name": "Jan Theuwis",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}05-09-2023 1 bestuurder benoemd, 1 ontslagnemend
- Tinne Glassée, Senior director medical shared services
- Bénédicte Van Maele, Senior director medical shared services
Technische details
{
"events": [
{
"kind": "director_out",
"role": "Senior Director Medical Shared Services",
"person": {
"rrn": null,
"name": "B\u00E9n\u00E9dicte Van Maele",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Senior Director Medical Shared Services",
"person": {
"rrn": null,
"name": "Tinne Glass\u00E9e",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}04-09-2023 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}13-09-2022 Carlo-Sébastien d'Addario benoemd tot commissaire
- Carlo-Sébastien d'Addario, Commissaire
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Carlo-S\u00E9bastien d\u0027Addario",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}30-04-2021 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 2021-04-23 · Algemene Vereniging van de Geneesmiddelenindustrie
- Filing: 2021-04-23 · Algemene Vereniging van de Geneesmiddelenindustrie
- General meeting: 2021-03-17 · Algemene Vereniging van de Geneesmiddelenindustrie
- Officer appointment: role: bestuurder, start_date: 2021-03-17 · Takeda Belgium N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · AbbVie N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Amgen N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Eli Lilly Benelux N.V.
- Officer reappointment: role: bestuurder, start_date: 2021-03-17 · Pfizer N.V.
- Officer resignation: role: bestuurder, end_date: 2021-03-17 · Merck N.V.
- Permanent representative · Laurerit Henaux
- Officer appointment: role: CEO, belast met het dagelijks bestuur · Caroline Ven
Technische details
{
"facts": [
{
"date": "2021-04-30",
"type": "publication",
"quote": "23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-04-23",
"type": "filing",
"quote": "neergelegd/ontvangen op ... 23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "general_meeting",
"quote": "ALGEMENE VERGADERING VAN 17 MAART 2021",
"value": "2021-03-17",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "officer_appointment",
"quote": "Benoeming van: 1. Takeda Belgium N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e2"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: 1. AbbVie N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e3"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 2. Amgen N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e4"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 3. Eli Lilly Benelux N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e5"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Herbenoeming van: ... 4. Pfizer N.V.",
"value": {
"role": "bestuurder",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e6"
},
{
"type": "officer_resignation",
"quote": "Ontslag van: 1. Merck N.V.",
"value": {
"role": "bestuurder",
"end_date": "2021-03-17"
},
"object": "e1",
"subject": "e7"
},
{
"type": "permanent_representative",
"quote": "Takeda Belgium NV heeft als vaste vertegenwoordiger de heer Laurerit Henaux",
"value": null,
"object": "e2",
"subject": "e8"
},
{
"type": "officer_appointment",
"quote": "Caroline Ven CEO, belast met het dagelijks bestuur",
"value": {
"role": "CEO, belast met het dagelijks bestuur"
},
"object": "e1",
"subject": "e9"
}
],
"act_meta": {
"outcome": "review",
"postfix": [
"publication date 2021-04-23 -\u003E edition 2021-04-30"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1820,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "company",
"name": "Algemene Vereniging van de Geneesmiddelenindustrie",
"attrs": {
"seat": "Terhulpsesteenweg 166, 1170 Brussel",
"legal_form": "Vereniging zonder Winstoogmerk",
"short_name": "AVGI"
}
},
{
"id": "e2",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium N.V.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie N.V.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen N.V.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux N.V.",
"attrs": {
"seat": "Markiesstraat 1, 1000 Brussel"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer N.V.",
"attrs": {
"seat": "Pleinlaan 17, 1050 Elsene"
}
},
{
"id": "e7",
"kbo": "0403.047.965",
"kind": "company",
"name": "Merck N.V.",
"attrs": {
"seat": "Brusselsesteenweg 288, 3090 Overijse"
}
},
{
"id": "e8",
"kbo": null,
"flag": "Name \u0027Laurerit\u0027 appears to be an OCR error for \u0027Laurent\u0027, but preserved as printed.",
"kind": "person",
"name": "Laurerit Henaux",
"attrs": {
"address": "avenue des B\u00E9cassines 26, 1160 Brussel",
"birth_date": "1966-04-27",
"birth_place": "Toulouse (Frankrijk)"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, belast met het dagelijks bestuur"
}
}
]
}30-04-2021 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 2021-01-01 · Association Générale de l'Industrie du Médicament
- Filing: 2021-04-23 · Association Générale de l'Industrie du Médicament
- General meeting: 2021-03-17 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: administrateur, start_date: 2021-03-17 · Takeda Belgium S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · AbbVie S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Amgen S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Eli Lilly Benelux S.A.
- Officer reappointment: role: administrateur, start_date: 2021-03-17 · Pfizer S.A.
- Officer resignation: date: 2021-03-17, role: administrateur · Merck S.A.
- Permanent representative · Laurent Henaux
Technische details
{
"facts": [
{
"date": "2021-04-30",
"type": "publication",
"quote": "1/2021",
"value": "2021-01-01",
"object": null,
"subject": "e1"
},
{
"date": "2021-04-23",
"type": "filing",
"quote": "neergelegd/ontvangen op 23 APR. 2021",
"value": "2021-04-23",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 17 MARS 2021",
"value": "2021-03-17",
"object": null,
"subject": "e1"
},
{
"date": "2021-03-17",
"type": "officer_appointment",
"quote": "Nomination de: 1. Takeda Belgium S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e2"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. AbbVie S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e3"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 2. Amgen S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e4"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 3. Eli Lilly Benelux S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e5"
},
{
"date": "2021-03-17",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 4. Pfizer S.A.",
"value": {
"role": "administrateur",
"start_date": "2021-03-17"
},
"object": "e1",
"subject": "e6"
},
{
"date": "2021-03-17",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 1. Merck S.A.",
"value": {
"date": "2021-03-17",
"role": "administrateur"
},
"object": "e1",
"subject": "e7"
},
{
"type": "permanent_representative",
"quote": "Takeda Belgium a d\u00E9sign\u00E9 comme repr\u00E9sentant permanent Monsieur Laurent Henaux",
"value": null,
"object": "e2",
"subject": "e8"
}
],
"act_meta": {
"outcome": "review",
"postfix": [
"publication date 2021-01-01 -\u003E edition 2021-04-30"
],
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1896,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 Bruxelles",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0403.054.202",
"kind": "company",
"name": "Takeda Belgium S.A.",
"attrs": {
"seat": "Leonardo Da Vincilaan 7, 1930 Zaventem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen S.A.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue du Marquis 1, 1000 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Ixelles"
}
},
{
"id": "e7",
"kbo": "0403.047.965",
"kind": "company",
"name": "Merck S.A.",
"attrs": {
"seat": "Brusselsesteenweg 288, 3090 Overijse"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Laurent Henaux",
"attrs": {
"address": "avenue des B\u00E9cassines 26, 1160 Bruxelles",
"birth_date": "1966-04-27",
"birth_place": "Toulouse (France)"
}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Caroline Ven",
"attrs": {
"role": "CEO, charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}09-09-2020 2 bestuurders benoemd
- Sandrine Ferrière, Bestuurder
- Frédéric Clais, Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}24-01-2020 3 bestuurders benoemd
- Sandrine Ferrière, Administrator
- Frédéric Clais, Administrator
- Ernst & Young Réviseurs d'Entreprises SC SCRL, Commissaire
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrator",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Ernst \u0026 Young R\u00E9viseurs d\u0027Entreprises SC SCRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}06-02-2019 2 bestuurders benoemd, 4 ontslagnemend
- Bénédicte Van Maele, Medical shared services lead
- Jan-Pieter Claeys, Sales & marketing lead diabetes and oncology belgium
- Michèle Sangeleer, Medical shared services lead
- Bert Macken, Sales and marketing leader oncology
- Egbert Thomas, Area director of elanco benelux and nordic
- Catherine de Mûelenaere, Head of marketing benelux and nordic
Technische details
{
"events": [
{
"kind": "director_out",
"role": "Medical Shared Services Lead",
"person": {
"rrn": null,
"name": "Mich\u00E8le Sangeleer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Medical Shared Services Lead",
"person": {
"rrn": null,
"name": "B\u00E9n\u00E9dicte Van Maele",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Sales and Marketing Leader Oncology",
"person": {
"rrn": null,
"name": "Bert Macken",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Sales \u0026 Marketing Lead Diabetes and Oncology Belgium",
"person": {
"rrn": null,
"name": "Jan-Pieter Claeys",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Area Director of Elanco Benelux and Nordic",
"person": {
"rrn": null,
"name": "Egbert Thomas",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Head of Marketing Benelux and Nordic",
"person": {
"rrn": null,
"name": "Catherine de M\u00FBelenaere",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}13-07-2018 2 bestuurders benoemd, 1 ontslagnemend
- Elisabeth Van Vleymen, Med lead & sr med advisor dermatology
- Ana Carla Franch, Site engagement manager, clinical operations belgium
- Kirsten Vandewalle, Regional clinical operations manager
Technische details
{
"events": [
{
"kind": "director_in",
"role": "Med Lead \u0026 Sr Med Advisor Dermatology",
"person": {
"rrn": null,
"name": "Elisabeth Van Vleymen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Regional Clinical Operations Manager",
"person": {
"rrn": null,
"name": "Kirsten Vandewalle",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Site Engagement Manager, Clinical Operations Belgium",
"person": {
"rrn": null,
"name": "Ana Carla Franch",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}13-07-2018 2 bestuurders benoemd
- Sandrine Ferrière, Bestuurder
- Frédéric Clais, Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}09-07-2018 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 09/07/2018 · Association Générale de l'Industrie du Médicament
- Filing: 20/06/2018 · Association Générale de l'Industrie du Médicament
- General meeting: 23/03/2018 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Amgen S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · AbbVie S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Celgene S.P.R.L.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Eli Lilly Benelux S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2018-03-23 · Pfizer S.A.
- Officer resignation: date: 2018-03-23, role: Membre du Conseil d'administration · Boehringer Ingelheim SCS
- Board meeting: 30/05/2018 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Président du Conseil d'administration, term: deux ans, start_date: 2018-05-30 · Pfizer S.A.
- Officer appointment: role: Vice-Président du Conseil d'administration, term: deux ans, start_date: 2018-05-30 · MSD Belgium
Technische details
{
"facts": [
{
"date": "2018-07-09",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 09/07/2018",
"value": "09/07/2018",
"object": null,
"subject": "e1"
},
{
"date": "2018-06-20",
"type": "filing",
"quote": "neergelegd/onvangen od 20 JUM 2018",
"value": "20/06/2018",
"object": null,
"subject": "e1"
},
{
"date": "2018-03-23",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 23 MARS 2018",
"value": "23/03/2018",
"object": null,
"subject": "e1"
},
{
"date": "2018-03-23",
"type": "officer_appointment",
"quote": "Nomination de : 1. Amgen S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 1. AbbVie S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 2. Celgene S.P.R.L.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 3. Eli Lilly Benelux S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: 4. Pfizer S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2018-03-23"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"term": null,
"start_date": "23/03/2018"
}
},
{
"date": "2018-03-23",
"type": "officer_resignation",
"quote": "D\u00E9mission de: 1. Boehringer Ingelheim SCS",
"value": {
"date": "2018-03-23",
"role": "Membre du Conseil d\u0027administration"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "23/03/2018",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2018-05-30",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 30 MAI 2018",
"value": "30/05/2018",
"object": null,
"subject": "e1"
},
{
"date": "2018-05-30",
"type": "officer_appointment",
"quote": "Pfizer ... a \u00E9t\u00E9 \u00E9lue pr\u00E9sident ... pour un mandat de deux ans",
"value": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": "deux ans",
"start_date": "2018-05-30"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": "deux ans",
"start_date": "30/05/2018"
}
},
{
"date": "2018-05-30",
"type": "officer_appointment",
"quote": "MSD Belgium ... a \u00E9t\u00E9 \u00E9lue Vice-Pr\u00E9sident ... pour un mandat de deux ans",
"value": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"term": "deux ans",
"start_date": "2018-05-30"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"term": "deux ans",
"start_date": "30/05/2018"
}
}
],
"act_meta": {
"outcome": "corrected",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1885,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "chauss\u00E9e de La Hulpe 166, 1170 BRUXELLES",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen S.A.",
"attrs": {
"seat": "Telecomlaan 5-7, 1831 Diegem"
}
},
{
"id": "e3",
"kbo": "0845.096.860",
"kind": "company",
"name": "AbbVie S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e4",
"kbo": "0882.012.387",
"kind": "company",
"name": "Celgene S.P.R.L.",
"attrs": {
"seat": "Place du Luxembourg 1, 1420 Braine-l\u0027Alleud"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue du Marquis 1, 1000 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Ixelles"
}
},
{
"id": "e7",
"kbo": "0435.953.632",
"kind": "company",
"name": "Boehringer Ingelheim SCS",
"attrs": {
"seat": "avenue Ariane 16, 1200 Woluwe-Saint-Lambert"
}
},
{
"id": "e8",
"kbo": null,
"kind": "company",
"name": "MSD Belgium",
"attrs": {}
},
{
"id": "e9",
"kbo": null,
"kind": "person",
"name": "Karel Van De Sompel",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Clarisse Lhoste",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Catherine Rutten",
"attrs": {}
}
]
}30-11-2017 5 bestuurders benoemd, 9 ontslagnemend
- Sandrine Ferrière
- Kirsten Vandewalle, Regional clinical operations manager
- Bert Macken, Sales and brand manager oncology
- Jérôme Barey, Manager compta générale, contrôle interne
- Catherine de Mûelenaere, Head of marketing benelux and nordic
- Peter Meijer
- Ana-Carla Franch
- Bruno van de Pol
Technische details
{
"events": [
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Peter Meijer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Ana-Carla Franch",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Bruno van de Pol",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Gerbert Trommel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Ramiro Cabral",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Hilde Carlier",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Colette Wodon",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Jan-Pieter Claeys",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "",
"person": {
"rrn": null,
"name": "Egbert Thomas",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Regional Clinical Operations Manager",
"person": {
"rrn": null,
"name": "Kirsten Vandewalle",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Sales and Brand Manager Oncology",
"person": {
"rrn": null,
"name": "Bert Macken",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Manager Compta G\u00E9n\u00E9rale, Contr\u00F4le interne",
"person": {
"rrn": null,
"name": "J\u00E9r\u00F4me Barey",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Head of Marketing Benelux and Nordic",
"person": {
"rrn": null,
"name": "Catherine de M\u00FBelenaere",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}21-03-2017 1 bestuurder benoemd, 1 ontslagnemend
- Sandrine Ferrière, Bestuurder
- Lambertus Verbakel, Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Lambertus Verbakel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}29-08-2016 Ernst & Young Réviseurs d'Entreprises SC SCRL benoemd tot auditor
- Ernst & Young Réviseurs d'Entreprises SC SCRL, Auditor
Technische details
{
"events": [
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "Ernst \u0026 Young R\u00E9viseurs d\u0027Entreprises SC SCRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}23-06-2016 9 bestuurders benoemd
- Fanny Verspeelt, Corporate affairs manager
- Sandrine Ferrière, Hr manager
- Michèle Sangeleer, Medical director
- Anne-Pascale Houtekie, Regulatory affairs manager and responsible pharmacist
- Ana-Carla Franch, Csm leader na
- Jan-Pieter Claeys, Sales and marketing lead for diabetes
- Peter Meijer, Business unit manager for oncology
- Karin Frijns, Customer meeting services associate
Technische details
{
"events": [
{
"kind": "director_in",
"role": "Corporate Affairs Manager",
"person": {
"rrn": null,
"name": "Fanny Verspeelt",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "HR Manager",
"person": {
"rrn": null,
"name": "Sandrine Ferri\u00E8re",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Medical Director",
"person": {
"rrn": null,
"name": "Mich\u00E8le Sangeleer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Regulatory Affairs Manager and Responsible Pharmacist",
"person": {
"rrn": null,
"name": "Anne-Pascale Houtekie",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "CSM Leader NA",
"person": {
"rrn": null,
"name": "Ana-Carla Franch",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Sales and Marketing Lead for Diabetes",
"person": {
"rrn": null,
"name": "Jan-Pieter Claeys",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Business Unit Manager for Oncology",
"person": {
"rrn": null,
"name": "Peter Meijer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Customer Meeting Services Associate",
"person": {
"rrn": null,
"name": "Karin Frijns",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Area Director of Elanco Benelux and Nordic",
"person": {
"rrn": null,
"name": "Egbert Thomas",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}09-12-2015 2 bestuurders benoemd, 2 ontslagnemend
- Frédéric Clais, Bestuurder
- Frédéric Clais, Gedelegeerd bestuurder
- Michel Collard, Bestuurder
- Michel Collard, Gedelegeerd bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Michel Collard",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Michel Collard",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Fr\u00E9d\u00E9ric Clais",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}04-06-2012 Act object · General meeting · Officer appointment · Officer reappointment
- Act object: Changements Conseil d'administration - Nomination Président et Vice-Président du Conseil d'administration · Association Générale de l'Industrie du Médicament
- Publication: 04/06/2012 · Association Générale de l'Industrie du Médicament
- Filing: 23/05/2012 · Association Générale de l'Industrie du Médicament
- General meeting: 23/03/2012 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Amgen S.A.
- Officer appointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Therabel Pharma S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Abbott S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Eli Lilly Benelux S.A.
- Officer reappointment: role: Membre du Conseil d'administration, start_date: 2012-03-23 · Pfizer S.A.
- Officer resignation: date: 2012-03-23, role: Membre du Conseil d'administration · AstraZeneca S.A.
- Officer resignation: date: 2012-03-23, role: Membre du Conseil d'administration · Sanofi Pasteur MSD S.A.
- Board meeting: 09/05/2012 · Association Générale de l'Industrie du Médicament
- Officer appointment: role: Président du Conseil d'administration, term: 2 ans, start_date: 2012-05-09 · Janssen-Cilag
- Officer appointment: role: Vice-Président du Conseil d'administration, term: 2 ans, start_date: 2012-05-09 · Eli Lilly Benelux S.A.
Technische details
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte: Changements Conseil d\u0027administration - Nomination Pr\u00E9sident et Vice-Pr\u00E9sident du Conseil d\u0027administration",
"value": "Changements Conseil d\u0027administration - Nomination Pr\u00E9sident et Vice-Pr\u00E9sident du Conseil d\u0027administration",
"object": null,
"subject": "e1"
},
{
"date": "2012-06-04",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 04/06/2012",
"value": "04/06/2012",
"object": null,
"subject": "e1"
},
{
"date": "2012-05-23",
"type": "filing",
"quote": "Groffe 23 MEI 2012",
"value": "23/05/2012",
"object": null,
"subject": "e1"
},
{
"date": "2012-03-23",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 23 MARS 2012",
"value": "23/03/2012",
"object": null,
"subject": "e1"
},
{
"date": "2012-03-23",
"type": "officer_appointment",
"quote": "Election de 5 nouveaux membres du Conseil d\u0027administration ... 1. Amgen S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e2",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_appointment",
"quote": "Election de 5 nouveaux membres du Conseil d\u0027administration ... 2. Therabel Pharma S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e3",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 1. Abbott S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e4",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 2. Eli Lilly Benelux S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de: ... 3. Pfizer S.A.",
"value": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "2012-03-23"
},
"object": "e1",
"subject": "e6",
"_value_raw": {
"role": "Membre du Conseil d\u0027administration",
"start_date": "23/03/2012"
}
},
{
"date": "2012-03-23",
"type": "officer_resignation",
"quote": "D\u00E9mission de : ... 1. AstraZeneca S.A.",
"value": {
"date": "2012-03-23",
"role": "Membre du Conseil d\u0027administration"
},
"object": "e1",
"subject": "e7",
"_value_raw": {
"date": "23/03/2012",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2012-03-23",
"type": "officer_resignation",
"quote": "D\u00E9mission de : ... 2. Sanofi Pasteur MSD S.A.",
"value": {
"date": "2012-03-23",
"role": "Membre du Conseil d\u0027administration"
},
"object": "e1",
"subject": "e8",
"_value_raw": {
"date": "23/03/2012",
"role": "Membre du Conseil d\u0027administration"
}
},
{
"date": "2012-05-09",
"type": "board_meeting",
"quote": "REUNION DU CONSEIL D\u0027ADMINISTRATION DU 9 MAI 2012",
"value": "09/05/2012",
"object": null,
"subject": "e1"
},
{
"date": "2012-05-09",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 9 mai 2012 Janssen-Cilag ... a \u00E9t\u00E9 \u00E9lue Pr\u00E9sident",
"value": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": "2 ans",
"start_date": "2012-05-09"
},
"object": "e1",
"subject": "e9",
"_value_raw": {
"role": "Pr\u00E9sident du Conseil d\u0027administration",
"term": "2 ans",
"start_date": "09/05/2012"
}
},
{
"date": "2012-05-09",
"type": "officer_appointment",
"quote": "Lors du Conseil d\u0027administration du 9 mai 2012 ... Eli Lilly Benelux ... a \u00E9t\u00E9 \u00E9lue Vice-Pr\u00E9sident",
"value": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"term": "2 ans",
"start_date": "2012-05-09"
},
"object": "e1",
"subject": "e5",
"_value_raw": {
"role": "Vice-Pr\u00E9sident du Conseil d\u0027administration",
"term": "2 ans",
"start_date": "09/05/2012"
}
}
],
"act_meta": {
"outcome": "clean",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1985,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0407.622.902",
"kind": "org",
"name": "Association G\u00E9n\u00E9rale de l\u0027Industrie du M\u00E9dicament",
"attrs": {
"seat": "ohauss\u00E9e de La Hulpe 166, 1170 BRUXELLES",
"legal_form": "Association sans But Lucratif",
"short_name": "AGIM"
}
},
{
"id": "e2",
"kbo": "0439.652.401",
"kind": "company",
"name": "Amgen S.A.",
"attrs": {
"seat": "avenue Ariane 5, 1200 Bruxelles"
}
},
{
"id": "e3",
"kbo": "0420.515.586",
"kind": "company",
"name": "Therabel Pharma S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 108, 1180 Uccle"
}
},
{
"id": "e4",
"kbo": "0403.044.007",
"kind": "company",
"name": "Abbott S.A.",
"attrs": {
"seat": "avenue Einstein 14, 1300 Wavre"
}
},
{
"id": "e5",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue de l\u0027Etuve 52, 1000 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Bruxelles"
}
},
{
"id": "e7",
"kbo": "0400.165.679",
"kind": "company",
"name": "AstraZeneca S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 110, 1180 Bruxelles"
}
},
{
"id": "e8",
"kbo": "0402.506.646",
"kind": "company",
"name": "Sanofi Pasteur MSD S.A.",
"attrs": {
"seat": "avenue Jules Bordet 13, 1140 Bruxelles"
}
},
{
"id": "e9",
"kbo": null,
"kind": "company",
"name": "Janssen-Cilag",
"attrs": {}
},
{
"id": "e10",
"kbo": null,
"kind": "person",
"name": "Sonja Willems",
"attrs": {}
},
{
"id": "e11",
"kbo": null,
"kind": "person",
"name": "Patricia Lanssiers",
"attrs": {}
},
{
"id": "e12",
"kbo": null,
"kind": "person",
"name": "Leo Neels",
"attrs": {
"role": "Directeur g\u00E9n\u00E9ral charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}20-04-2009 General meeting · Officer appointment · Officer reappointment · Officer resignation
- Publication: 20/04/2009
- Filing: 09-04-2009
- General meeting: 27/03/2009
- Officer appointment: role: administrateur, start_date: 2009-03-27 · Abbott S.A.
- Officer appointment: role: administrateur, start_date: 2009-03-27 · Sanofi Pasteur MSD S.A.
- Officer reappointment: role: administrateur, start_date: 2009-03-27 · Eli Lilly Benelux S.A.
- Officer reappointment: role: administrateur, start_date: 2009-03-27 · Pfizer S.A.
- Officer reappointment: role: administrateur, start_date: 2009-03-27 · Schering-Plough S.A.
- Officer resignation: date: 2009-03-27, role: administrateur · AstraZeneca S.A.
- Officer resignation: date: 2009-03-27, role: administrateur · Therabel Pharma S.A.
Technische details
{
"facts": [
{
"date": "2009-04-20",
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 20/04/2009",
"value": "20/04/2009",
"object": null,
"subject": null
},
{
"date": "2009-04-09",
"type": "filing",
"quote": "09-04-2009 Greffe",
"value": "09-04-2009",
"object": null,
"subject": null
},
{
"date": "2009-03-27",
"type": "general_meeting",
"quote": "ASSEMBLEE GENERALE DU 27 MARS 2009",
"value": "27/03/2009",
"object": null,
"subject": null
},
{
"date": "2009-03-27",
"type": "officer_appointment",
"quote": "Nomination de : 1. Abbott S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e1",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_appointment",
"quote": "Nomination de : 2. Sanofi Pasteur MSD S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e2",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de : 1.. Eli Lilly Benelux S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e3",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de : 2, Pfizer S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e4",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_reappointment",
"quote": "Reconduction de la nomination de : 3. Schering-Plough S.A.",
"value": {
"role": "administrateur",
"start_date": "2009-03-27"
},
"object": null,
"subject": "e5",
"_value_raw": {
"role": "administrateur",
"start_date": "27/03/2009"
}
},
{
"date": "2009-03-27",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 1. AstraZeneca S.A.",
"value": {
"date": "2009-03-27",
"role": "administrateur"
},
"object": null,
"subject": "e6",
"_value_raw": {
"date": "27/03/2009",
"role": "administrateur"
}
},
{
"date": "2009-03-27",
"type": "officer_resignation",
"quote": "D\u00E9mission de : 2. Therabel Pharma S.A.",
"value": {
"date": "2009-03-27",
"role": "administrateur"
},
"object": null,
"subject": "e7",
"_value_raw": {
"date": "27/03/2009",
"role": "administrateur"
}
}
],
"act_meta": {
"outcome": "corrected",
"model_id": 50,
"verified": true,
"extractor": "verified-v1",
"ocr_chars": 1684,
"truncated": false
},
"entities": [
{
"id": "e1",
"kbo": "0403.044.007",
"kind": "company",
"name": "Abbott S.A.",
"attrs": {
"seat": "Parc Scientifique, rue du Bosquet 2, 1348 Ottignies-Louvain-La-Neuve"
}
},
{
"id": "e2",
"kbo": "0402.506.646",
"kind": "company",
"name": "Sanofi Pasteur MSD S.A.",
"attrs": {
"seat": "avenue Jules Bordet 13, 1140 Bruxelles"
}
},
{
"id": "e3",
"kbo": "0406.754.454",
"kind": "company",
"name": "Eli Lilly Benelux S.A.",
"attrs": {
"seat": "rue de l\u0027Etuve 52 bo\u00EEte 1, 1000 Bruxelles"
}
},
{
"id": "e4",
"kbo": "0401.994.823",
"kind": "company",
"name": "Pfizer S.A.",
"attrs": {
"seat": "boulevard de la Plaine 17, 1050 Bruxelles"
}
},
{
"id": "e5",
"kbo": "0406.820.770",
"kind": "company",
"name": "Schering-Plough S.A.",
"attrs": {
"seat": "rue de Stalle 73, 1180 Bruxelles"
}
},
{
"id": "e6",
"kbo": "0400.165.679",
"kind": "company",
"name": "AstraZeneca S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 110, 1180 Bruxelles"
}
},
{
"id": "e7",
"kbo": "0420.515.586",
"kind": "company",
"name": "Therabel Pharma S.A.",
"attrs": {
"seat": "rue Egide Van Ophem 108, 1180 Bruxelles"
}
},
{
"id": "e8",
"kbo": null,
"kind": "person",
"name": "Leo Neels",
"attrs": {
"role": "Directeur g\u00E9n\u00E9ral charg\u00E9 de la gestion journali\u00E8re"
}
}
]
}14-06-2004 1 bestuurder benoemd, 2 ontslagnemend
- Eric Janvier, Bestuurder
- Gordon Boyd Coutts, Gedelegeerd bestuurder
- Gordon Boyd Coutts, Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur-d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Gordon Boyd Coutts",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Gordon Boyd Coutts",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Eric Janvier",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0406.754.454",
"name_full": "Eli Lilly Benelux"
}
}| Officiële naamFR | Eli Lilly Benelux |